Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Completed · Phase 1

Conditions studied: Hematological Malignancies

In brief

ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.

Key facts

Study ID

NCT00047489

Run by

M.D. Anderson Cancer Center

People needed

32

Starts

2002-12-01

Expected to finish

2005-01-01

Last updated by the study team

2018-10-31

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with relapsed or refractory acute leukemias (AML, ALL, MDS [RAEB, RAEBT], CMML in transformation with >/= 10% peripheral blood/bone marrow blasts, CML in blast crisis), and patients with relapsed/refractory or transformed CLL.
• Signed informed consent indicating that patients are aware of the investigational nature of this study, and in keeping with the policies of this hospital.
• ECOG performance status </= 2.
• Serum direct bilirubin </= 2 mg/dL, serum SGOT or SGPT < 3 upper limit of normal, serum creatinine </= 2 mg/dL, unless considered due to organ leukemic involvement.
• Age > 16 years - a separate Phase I study is being conducted in the pediatric population.

You may not qualify if…

• Any severe, concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for study entry.
• Pregnant and/or lactating females.
• Those with documented sulfonamide allergy should be excluded from study participation.

Where it is running

• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.